Moderna Inc at Barclays Global Healthcare Conference Transcript
Hi guys, good morning. Welcome to Sunny Miami. I'm Ellie Merle, one of the Biotech Analyst here at Barclays. Very happy to have Lavina Taluktar here with us today, Head of Investor Relations at Moderna. It's been a very eventful year for you.
So maybe if you could, start with an overview of some of the key highlights for Moderna over '25 and into the first quarter of '26.
Sure, thank you so much for having me, Ellie. This is great to be here. For 2025, I characterize 2025 as a year of execution, and we really executed on all fronts. On the revenue side, we came in at $1.9 billion which is up towards the high end of the revenue range we gave on the third quarter call.
And that was really driven by execution from the commercial teams. We were very happy to get mNEXSPIKE, our second COVID vaccine approved in June, and they really executed and made sure that that was available on the market for the fall season. We also brought down costs
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
